MétaCan
Menu
Back to cohort
Record W4220938665 · doi:10.1136/bmjopen-2021-057656

Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)

2022· article· en· W4220938665 on OpenAlexaff
Konstantinos Papamichael, Vipul Jairath, Guangyong Zou, Benjamin L. Cohen, Timothy E. Ritter, Bruce E. Sands, Corey A. Siegel, John F. Valentine, Michelle I. Smith, Niels Vande Casteele, Marla C. Dubinsky, Adam S. Cheifetz

Bibliographic record

VenueBMJ Open · 2022
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsWestern University
FundersGenentechF. Hoffmann-La RocheIronwood Pharmaceuticals, IncorporatedGrifolsSun PharmaMitsubishi Tanabe Pharma CorporationCelltrionMylanCrohn's and Colitis FoundationTakeda Pharmaceuticals U.S.A.Teva Pharmaceutical IndustriesLeona M. and Harry B. Helmsley Charitable TrustBoston PharmaceuticalsGilead SciencesSanofiGlaxoSmithKlineAllerganAstraZenecaSeres TherapeuticsAmgenPfizerCelgeneCelltrion HealthcareEli Lilly and CompanyBristol-Myers Squibb
KeywordsMedicineProtocol (science)InfliximabCrohn's diseaseOpen labelClinical trialDiseaseStandard of careRandomized controlled trialDashboardOpen label studyPhysical therapyAlternative medicineInternal medicineAdverse effectPathologyData science

Abstract

fetched live from OpenAlex

INTRODUCTION: Preliminary data indicates that proactive therapeutic drug monitoring (TDM) is associated with better outcomes compared with empiric dose escalation and/or reactive TDM, and that pharmacokinetic (PK) modelling can improve the precision of individual dosing schedules in Crohn's disease (CD). However, there are no data regarding the utility of a proactive TDM combined PK-dashboard starting early during the induction phase, when disease activity and drug clearance are greatest. The aim of this randomised, controlled, multicentre, open-label trial is to evaluate the efficacy and safety of a proactive TDM combined PK dashboard-driven infliximab dosing compared with standard of care (SOC) dosing in patients with moderately to severely active CD. METHODS AND ANALYSIS: Eligible adolescent and adult (aged ≥16-80 years) patients with moderately to severely active CD will be randomised 1:1 to receive either infliximab monotherapy with proactive TDM using a PK dashboard (iDose, Projections Research) or SOC infliximab therapy, with or without a concomitant immunomodulator (IMM) (thiopurine or methotrexate) at the discretion of the investigator. The primary outcome of the study is the proportion of subjects with sustained corticosteroid-free clinical remission and no need for rescue therapy from week 14 throughout week 52. Rescue therapy is defined as any IFX dose escalation other than what is forecasted by iDose either done empirically or based on reactive TDM; addition of an IMM after week 2; reintroduction of corticosteroids after initial tapering; switch to another biologic or need for CD-related surgery. The secondary outcomes will include both efficacy and safety end points, such as endoscopic and biological remission, durability of response and CD-related surgery and hospitalisation. ETHICS AND DISSEMINATION: The protocol has been approved by the Institutional Review Board Committee of the Beth Israel Deaconess Medical Center (IRB#:2021P000391). Results will be disseminated in peer-reviewed journals and presented at scientific meetings. TRIAL REGISTRATION NUMBER: NCT04835506.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Direct model labels (unvalidated)

Per-model category and study-design labels from the labeling rounds. They are machine output, unvalidated, and the disagreement between models ships as data. No study design here is MEDLINE-validated yet.

Model armCategoriesStudy designConfidence
gemmano category
Domain: not available · Genre: Protocol
About the Canadian research system: no · About a Canadian topic: no
Randomized triallow
gptno category
Domain: not available · Genre: Protocol
About the Canadian research system: no · About a Canadian topic: no
Randomized trialhigh
models agreeAgreement compares identical category sets and study designs across arms.

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.023
metaresearch head score (Gemma)0.022
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.051
Threshold uncertainty score0.170

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0230.022
Meta-epidemiology (narrow)0.0050.002
Meta-epidemiology (broad)0.0090.006
Bibliometrics0.0020.002
Science and technology studies0.0020.004
Scholarly communication0.0040.004
Open science0.0030.002
Research integrity0.0060.007
Insufficient payload (model declined to judge)0.0510.011

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.062
GPT teacher head0.414
Teacher spread0.351 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Labeled directly by 2 models reading the full record.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations29
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueBMJ OpenSame topicInflammatory Bowel DiseaseFrench-language works237,207